Skip to content

Prospective, observational, Multicenter real-world study of traditional Chinese medicine in the treatment of adenoid hypertrophy in children

Prospective, observational, multicenter real-world study of traditional Chinese medicine in the treatment of adenoid hypertrophy in children

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2023000018
Enrollment
Unknown
Registered
2023-06-15
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric adenoid hypertrophy

Interventions

non-exposure group:Symptomatic treatment with western medicine
exposure group:traditional Chinese medicine treatment based on syndrome differentiation (including the prescription of invigorating qi and blood to shrink adenoids),and patches treatment

Sponsors

Affiliated Hospital of Nanjing University of Chinese Medicine(Jiangsu Hospital of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1.Age ranges from 6 months to 14 years old, regardless of gender 2.Meet the diagnostic criteria of Western medicine for adenoid hypertrophy; 3.The children's family gave informed consent and volunteered for the test. The process of obtaining informed consent shall comply with GCP regulations

Exclusion criteria

Exclusion criteria: 1.Those who do not meet the inclusion criteria; 2.Those who have received other adenoid hypertrophy drugs treatment within 2 weeks 3.Those who are allergic to the test drug 4.People with serious primary diseases or acute attacks of infectious diseases such as heart, liver, kidney, digestive and hematopoietic systems 5.Those with severe nasal septal deviation, nasal polyps, laryngeal and tracheal diseases that cause breathing difficulties 6.Accompanied by serious complications such as pulmonary heart disease, pulmonary hypertension, etc

Design outcomes

Primary

MeasureTime frame
Ratio of Adenoid thickness to nasopharyngeal width;Sleep snoring relief rate and relief time;nasal obstruction relief rate and relief time;Open mouth breathing relief rate and relief time;

Secondary

MeasureTime frame
runny nose relief rate;Weak and lazy speech relief rate;A dull complexion relief rate;Profuse sweating relief rate;Pharyngeal discomfort relief rate;Dizziness and headache relief rate;poor appetite relief rate;Loose stools or constipation relief rate;Combined use rate of antibiotics;cough relief rate;

Countries

China

Contacts

Public Contactyuanbin

Jiangsu Province Hospital of Chinese Medicine

yfy0045@njucm.edu.cn13851463308

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026